Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02391116 |
|
Recruitment Status :
Completed
First Posted : March 18, 2015
Results First Posted : January 8, 2018
Last Update Posted : January 4, 2019
|
Sponsor:
Bayer
Information provided by (Responsible Party):
Bayer
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
To assess the potential efficacy (in terms of objective response) of single agent copanlisib in patients with relapsed or refractory Diffuse large B-cell lymphoma (DLBCL) and assess the relationship between efficacy and a potentially predictive biomarker
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Diffuse, Large B-Cell, Lymphoma | Drug: Copanlisib (Aliqopa, BAY80-6946) | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 67 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | An Open-label, Single-arm Phase II Study in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) to Evaluate Efficacy and Safety of Treatment With Single Agent Copanlisib and the Impact of Biomarkers Thereupon. |
| Actual Study Start Date : | May 8, 2015 |
| Actual Primary Completion Date : | July 5, 2016 |
| Actual Study Completion Date : | January 19, 2018 |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
Lymphoma
Drug Information available for:
Copanlisib
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Copanlisib (Aliqopa, BAY80-6946)
Copanlisib (Aliqopa, BAY80-6946) solution for IV infusion (test drug/investigational medicinal product)
|
Drug: Copanlisib (Aliqopa, BAY80-6946)
Participants assigned to receive copanlisib intravenous (IV) infusion at a dose of 60 mg as single agent on Days 1, 8, and 15 of 28-day treatment cycle. Copanlisib treatment was to be continued until disease progression (PD), unacceptable toxicity, or until another criterion was met for withdrawal from the study treatment |
Primary Outcome Measures :
- Objective Response Rate (ORR) in Total Population Based on Investigator Assessment [ Time Frame: From start of study treatment assessed up to 24 weeks after the last participant fully evaluable for the primary endpoint started treatment (about 12 months) ]The objective response rate (ORR) was defined as the percentage of participants who had at least one post-baseline overall response of complete response (CR) or partial response (PR) during study conduct according to the criteria defined by the Lugano Classification, 2014 and assessed by CT/MRI/PET-CT. The primary efficacy overall response assessment was based on investigator assessment of response.
- ORR by CD79b Status Based on Investigator Assessment [ Time Frame: From start of study treatment assessed up to 24 weeks after the last participant fully evaluable for the primary endpoint started treatment (about 12 months) ]The objective response rate (ORR) was defined as the percentage of participants who had at least one post-baseline overall response of complete response (CR) or partial response (PR) during study conduct according to the criteria defined by the Lugano Classification, 2014 and assessed by CT/MRI/PET-CT. The primary efficacy overall response assessment was based on investigator assessment of response.
- ORR by DLBCL/COO Subtype Based on Investigator Assessment [ Time Frame: From start of study treatment assessed up to 24 weeks after the last participant fully evaluable for the primary endpoint started treatment (about 12 months) ]The objective response rate (ORR) was defined as the percentage of participants who had at least one post-baseline overall response of complete response (CR) or partial response (PR) during study conduct according to the criteria defined by the Lugano Classification, 2014 and assessed by CT/MRI/PET-CT. The primary efficacy overall response assessment was based on investigator assessment of response.
Secondary Outcome Measures :
- Duration of Response (DOR) in Total Population [ Time Frame: From start of study treatment assessed up to 2 years after the last participant's first treatment or the last participant dies, whichever occurs first ]The duration of response (DOR) was defined as the time from the date of first observed overall response (CR or PR) until radiological PD or death due to any cause, whichever was earlier. DOR was defined for responders only (i.e. participants with a best response of CR or PR), based on the investigator assessment of tumor response according to the criteria defined by the Lugano Classification, 2014 and assessed by CT/MRI/PET-CT.
- DOR by CD79b Status [ Time Frame: From start of study treatment assessed up to 2 years after the last participant's first treatment or the last participant dies, whichever occurs first ]The duration of response (DOR) was defined as the time from the date of first observed overall response (CR or PR) until radiological PD or death due to any cause, whichever was earlier. DOR was defined for responders only (i.e. participants with a best response of CR or PR), based on the investigator assessment of tumor response according to the criteria defined by the Lugano Classification, 2014 and assessed by CT/MRI/PET-CT.
- DOR by DLBCL/COO Subtype [ Time Frame: From start of study treatment assessed up to 2 years after the last participant's first treatment or the last participant dies, whichever occurs first ]The duration of response (DOR) was defined as the time from the date of first observed overall response (CR or PR) until radiological PD or death due to any cause, whichever was earlier. DOR was defined for responders only (i.e. participants with a best response of CR or PR), based on the investigator assessment of tumor response according to the criteria defined by the Lugano Classification, 2014 and assessed by CT/MRI/PET-CT.
- Progression-free Survival (PFS) in Total Population [ Time Frame: From start of study treatment assessed up to 2 years after the last participant's first treatment or the last participant dies, whichever occurs first ]The progression-free survival (PFS) was defined as the time from date of start of study treatment to radiological PD or death due to any cause, whichever was earlier, based on the investigator assessment of tumor response according to the criteria defined by the Lugano Classification, 2014 and assessed by CT/MRI/PET-CT.
- PFS by CD79b Status [ Time Frame: From start of study treatment assessed up to 2 years after the last participant's first treatment or the last participant dies, whichever occurs first ]The progression-free survival (PFS) was defined as the time from date of start of study treatment to radiological PD or death due to any cause, whichever was earlier, based on the investigator assessment of tumor response according to the criteria defined by the Lugano Classification, 2014 and assessed by CT/MRI/PET-CT.
- PFS by DLBCL/COO Subtype [ Time Frame: From start of study treatment assessed up to 2 years after the last participant's first treatment or the last participant dies, whichever occurs first ]The progression-free survival (PFS) was defined as the time from date of start of study treatment to radiological PD or death due to any cause, whichever was earlier, based on the investigator assessment of tumor response according to the criteria defined by the Lugano Classification, 2014 and assessed by CT/MRI/PET-CT.
- Overall Survival (OS) in Total Population [ Time Frame: From start of study treatment assessed up to 2 years after the last participant's first treatment or the last participant dies, whichever occurs first ]The overall survival (OS) was defined as the time from date of start of study treatment until death from any cause.
- OS by CD79b Status [ Time Frame: From start of study treatment assessed up to 2 years after the last participant's first treatment or the last participant dies, whichever occurs first ]The overall survival (OS) was defined as the time from date of start of study treatment until death from any cause.
- OS by DLBCL/COO Subtype [ Time Frame: From start of study treatment assessed up to 2 years after the last participant's first treatment or the last participant dies, whichever occurs first ]The overall survival (OS) was defined as the time from date of start of study treatment until death from any cause.
- Duration of Stable Disease (DOSD) in Total Population [ Time Frame: From start of study treatment assessed up to 2 years after the last participant's first treatment or the last participant dies, whichever occurs first ]The duration of stable disease (DOSD) was defined as the time (in days) from date of start of study treatment to radiological PD or death due to any cause, whichever was earlier. The DOSD was only evaluated in participants failing to achieve a best response of CR or PR, but who achieved SD (stable disease), based on the investigator assessment of tumor response according to the criteria defined by the Lugano Classification, 2014 and assessed by CT/MRI/PET-CT.
- Disease Control Rate (DCR) in Total Population [ Time Frame: From start of study treatment assessed up to 2 years after the last participant's first treatment or the last participant dies, whichever occurs first ]The disease control rate (DCR) was defined as the percentage of participants who had a best response rating of CR, PR, or SD that was achieved during treatment or within 30 days after termination of study drug. The tumor response was based on investigator assessment according to the criteria defined by the Lugano Classification, 2014 and assessed by CT/MRI/PET-CT.
- DCR by CD79b Status [ Time Frame: From start of study treatment assessed up to 2 years after the last participant's first treatment or the last participant dies, whichever occurs first ]The disease control rate (DCR) was defined as the percentage of participants who had a best response rating of CR, PR, or SD that was achieved during treatment or within 30 days after termination of study drug. The tumor response was based on investigator assessment according to the criteria defined by the Lugano Classification, 2014 and assessed by CT/MRI/PET-CT.
- DCR by DLBCL/COO Subtype [ Time Frame: From start of study treatment assessed up to 2 years after the last participant's first treatment or the last participant dies, whichever occurs first ]The disease control rate (DCR) was defined as the percentage of participants who had a best response rating of CR, PR, or SD that was achieved during treatment or within 30 days after termination of study drug. The tumor response was based on investigator assessment according to the criteria defined by the Lugano Classification, 2014 and assessed by CT/MRI/PET-CT.
- Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) [ Time Frame: From start of test drug to 30 days after the last test drug intake, assessed up to 2 years after the last participant's first treatment or the last participant dies (whichever occurs first), with an average of 15 weeks for individual participant ]A TEAE was defined as any event arising or worsening after the start of study drug administration until 30 days after the last application.
Other Outcome Measures:
- Time to Response (TTR) in Total Population [ Time Frame: From start of study treatment assessed up to 2 years after the last participant's first treatment or the last participant dies, whichever occurs first ]The time to response (TTR) was defined as the time (days) from start of study treatment to the date of first observed response (first measured CR or PR). TTR was defined for responders only (i.e. participants with CR or PR), based on the investigator assessment of tumor response according to the criteria defined by the Lugano Classification, 2014 and assessed by CT/MRI/PET-CT.
- ORR in Total Population Based on Central Imaging Review [ Time Frame: From start of study treatment assessed up to 24 weeks after the last participant fully evaluable for the primary endpoint started treatment (about 12 months) ]The objective response rate (ORR) was defined as the percentage of participants who had at least one post-baseline overall response of complete response (CR) or partial response (PR) during study conduct according to the criteria defined by the Lugano Classification, 2014 and assessed by CT/MRI/PET-CT. The overall response assessment for this outcome measure was based on central imaging review.
- ORR by CD79b Status Based on Central Imaging Review [ Time Frame: From start of study treatment assessed up to 24 weeks after the last participant fully evaluable for the primary endpoint started treatment (about 12 months) ]The objective response rate (ORR) was defined as the percentage of participants who had at least one post-baseline overall response of complete response (CR) or partial response (PR) during study conduct according to the criteria defined by the Lugano Classification, 2014 and assessed by CT/MRI/PET-CT. The overall response assessment for this outcome measure was based on central imaging review.
- ORR by DLBCL/COO Subtype Based on Central Imaging Review [ Time Frame: From start of study treatment assessed up to 24 weeks after the last participant fully evaluable for the primary endpoint started treatment (about 12 months) ]The objective response rate (ORR) was defined as the percentage of participants who had at least one post-baseline overall response of complete response (CR) or partial response (PR) during study conduct according to the criteria defined by the Lugano Classification, 2014 and assessed by CT/MRI/PET-CT. The overall response assessment for this outcome measure was based on central imaging review.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Diagnosis of Diffuse large B-cell lymphoma (DLBCL) (de novo or DLBCL transformed from follicular lymphoma on the basis of a tissue biopsy).
- Received at least one prior therapy for aggressive Non-Hodgkin's Lymphoma (NHL) (DLBCL).
- Received CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) + rituximab or equivalent regimen.
- Patients must have measurable disease.
- Not eligible or not willing to receive the high-dose (myeloablative) chemotherapy (HDC) and stem cell transplant (SCT).
- A fresh tumor biopsy collected during screening and /or archival tumor tissue collected after the last relapse/disease progression.
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2.
- Left ventricular ejection fraction (LVEF) ≥ the lower limit of normal (LLN) for the Institution. (as per local standard of care) as measured by echocardiogram (ECHO) or Multiple gated acquisition (MUGA) scan.
- Adequate bone marrow, liver and renal function.
Exclusion Criteria:
- Any of the following as the only site(s) of disease: palpable lymph nodes not visible on imaging studies, skin lesions, or bone marrow involvement only.
- Active CTCAE (Common Terminology Criteria for Adverse Events) Grade 3/4 infection.
- Current central nervous system (CNS) involvement by lymphoma.
- Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months). Myocardial infarction within the past 6 months before start of study treatment.
- Uncontrolled arterial hypertension despite optimal medical management (per investigator's opinion).
- Type I or II diabetes mellitus with HbA1c > 8.5% at Screening.
- New York Heart Association (NYHA) class III or IV heart disease.
- History or concurrent condition of interstitial lung disease of any severity and/or severely impaired lung function (as judged by the investigator).
- Patients who previously received therapy with copanlisib or other PI3K inhibitors are not eligible for enrollment.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02391116
Locations
| Australia, New South Wales | |
| Kingswood, New South Wales, Australia, 2747 | |
| Australia, Victoria | |
| Ballarat, Victoria, Australia, 3350 | |
| Prahran, Victoria, Australia, 3181 | |
| Australia | |
| Box Hill, Australia, 3128 | |
| Belgium | |
| Wilrijk, Antwerpen, Belgium, 2610 | |
| Bruxelles - Brussel, Belgium, 1200 | |
| Edegem, Belgium, 2650 | |
| Gent, Belgium, 9000 | |
| Leuven, Belgium, 3000 | |
| Canada, Newfoundland and Labrador | |
| St. John's, Newfoundland and Labrador, Canada, A1B 3V6 | |
| Canada, Ontario | |
| Brampton, Ontario, Canada, L6R 3J7 | |
| Canada, Quebec | |
| Montreal, Quebec, Canada, H1T 2M4 | |
| Montreal, Quebec, Canada, H3T 1E2 | |
| Sherbrooke, Quebec, Canada, J1H 5N4 | |
| Denmark | |
| Aarhus C, Denmark, 8000 | |
| Odense C, Denmark, 5000 | |
| France | |
| Caen Cedex, France, 14033 | |
| Creteil, France, 94010 | |
| Lille, France, 59037 | |
| PARIS cedex, France, 75475 | |
| Pierre Benite, France, 69310 | |
| POITIERS cedex, France, 86021 | |
| Germany | |
| Münster, Nordrhein-Westfalen, Germany, 48149 | |
| Leipzig, Sachsen, Germany | |
| Berlin, Germany, 10967 | |
| Italy | |
| Milano, Lombardia, Italy, 20089 | |
| Korea, Republic of | |
| Seoul, Korea, Republic of, 05505 | |
| Seoul, Korea, Republic of, 110-744 | |
| Singapore | |
| Singapore, Singapore, 169610 | |
| United Kingdom | |
| Truro, Cornwall, United Kingdom, TR1 3LJ | |
| Southampton, Hampshire, United Kingdom, SO16 6YD | |
| London, United Kingdom, NW1 2PG | |
Sponsors and Collaborators
Bayer
Investigators
| Study Director: | Bayer Study Director | Bayer |
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Bayer |
| ClinicalTrials.gov Identifier: | NCT02391116 |
| Other Study ID Numbers: |
17119 2014-004848-36 ( EudraCT Number ) |
| First Posted: | March 18, 2015 Key Record Dates |
| Results First Posted: | January 8, 2018 |
| Last Update Posted: | January 4, 2019 |
| Last Verified: | December 2018 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Lymphoma Lymphoma, Large B-Cell, Diffuse Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders |
Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Lymphoma, B-Cell Lymphoma, Non-Hodgkin |